

Curriculum Vitae

NAME: ROSCIGNO GIORGIO

BIRTH: 08/12/1947 – Asmara, Eritrea

CIVIL STATUS: married with two daughters

NATIONALITY: Italian :

Education

1965-1972

. Università Cattolica del Sacro Cuore Facoltà' di Medicina e Chirurgia - Rome

1983

Tropical Epidemiology, Institute of Tropical Medicine Amsterdam - Netherlands

1984

Advanced Clinical Trials Management, London – UK.

1988

Diploma in Tropical Medicine and Health, New York Medical College, New York, USA.

Advisory

Professional

Services /

Membership

Member of UNITAID JRC (Experts Review Committee) 2018 now.

Member of the Editorial Board of the Journal for Neglected Tropical Diseases 2015 to now

Founder and Chair of the Board Next2People Switzerland (Geneva) 2015 now

Founder and Chair of the Board Next2People South Africa (Pretoria)

Founder and Chair of the Board Next2People Ethiopia (Addis Abeba).

Co Founder and Chief Operating Officer African Society for Laboratory Medicine Addis Abeba 2012 to 2013

Stop TB Coordinating Board ; member and Chair of the Diagnostic Working Group from 2003 to 2012

Member of the Executive Committee of the Stop TB Coordinating Board 2007 -2012

STOP TB COORDINATING BOARD: Chair of the New Drugs Working Group 2000-2003.

Member of GLI since 2011.

GLOBAL DRUG FACILITY: Technical Review Committee member (2002 -2008)

**Professional
Experiences**

Member of the External Review Team of the Ethiopian TB Control Program : focus on PPM Laboratory Strengthening and Case Finding : preparation for Global Fund Submission : 15 November 10 December 2019.

Member and URC partner in the ETBE USAID writing Proposal for Ethiopian TB Control Program (Laboratory Strengthening and PPM). January 2020.

2015 January to July
Consultant to WHO for the Ethiopian Pharmaceutical Development Plan

2015 till now
Founder and Executive Chair of the Board/ Chief Operating Officer
NEXT2PEOPLE Pretoria / Geneva

2012 to 2020
Chief Operating Officer
African Society for Laboratory Medicine Addis Abeba

2003-2011
Chief Executive Officer of FIND
Foundation for Innovative New Diagnostics Geneva

2000-2002
Co-Founder ,Acting Chief Executive Officer / Senior Advisor/ Director of Strategic Development
Global Alliance for TB Drug Development, Brussels (Belgium) – New York (USA)

1998-2000 Aventis International
International Medical Director Anti-infective, Paris, France

1996-1998 Hoechst Marion Roussel
Global Rifamycin Development Director, -Milan

1993-1996
Global Medical Development Director Milan, Italy.

1990-1993 Marion Merrell Dow
Clinical Research Director Europe – Anti-infectives, Winnersh, UK.

1987-1990 Merrell Dow Research Institute
DFMO / EFLORNITHINE / Clinical Research leader,
Medical Director for South East Asia
Global Rifamycin Director, Strasbourg France

1982-1987 Dow Lepetit Merrell Dow
Medical Director Africa,
Rifamycin Global Medical Director, Geneva, Switzerland

1981 Impresa Sapiem
Health Director, Hassimessaoud, Algeria

1979-1982 Ospedale Civile di Arezzo
Medical Intern

1977-1978
Health Director, Kosti, Sudan

1976 Impresa Astaldi
Health Director, Kinshasa, Zaire.

1974-1975 Italian Embassy
Coordinator of Health Activities, Addis Ababa, Ethiopia

1972-1974 Ospedale Italiano - Hospitem:
Medical Internship and assistant to the Medical Director, Asmara Ethiopia.

Highlights and Achievements

As Medical Director for Africa:

- Developed the concept and obtained the registration of Rifater, fixed dose combination for the treatment of tuberculosis in most African countries (South Africa, Algeria, Kenya, Ivory Coast, Zambia, Ethiopia and others)
- Coordinated all African Studies on Eflornitine in the treatment of sleeping sickness and compiled clinical data, which obtained FDA approval in 1989

As Medical Director for Asia:

- Conducted intense clinical development activities that led to registration of Targocid ®(Teicoplanin) and Vigabatrin ® (anti-epileptic) in South Korea, Hong Kong, Taiwan, the Philippines, Pakistan and India.
- Coordinated multiple clinical trials for the registration of TB fixed drug combinations throughout Thailand, China, Philippines and Pakistan

As European Clinical Research Director for Anti-infective:

- Prepared Clinical Development Plans for Rifapentine (approved by FDA), Teicoplanin in neonates (approved in Europe in 1992) and treatment of chloroquine resistant malaria and P. Carini infection in AIDS patients.

As Rifamycin Global Development Director:

- Contributed to numerous International meetings with the WHO and the International Union Against Tuberculosis and Lung Disease, to the new “Treatment guidelines on Tuberculosis”
- Represented Industry perspectives on quality assurance of fixed dose combinations in TB

As Rifamycin Global Development Director – Aventis:

- Provided to Merrell Dow the strategic medical guidance for the fixed dose combinations in tuberculosis

As International Medical Director Anti-infective

- Managed the overall Anti-infective Aventis Portfolio, within its International Division. Resubmitted and managed a “rescue” clinical operating plan for Rifapentine.

As Acting CEO/Senior Advisor of the Global Alliance for TB Drug Development.

- Opened offices in New York, Brussels and Cape Town including: hiring local administrative personnel and furnishing the facilities
- Selected and recruited the Advocacy Director, and pre-selected to a short list in the R&D directors and the Business Development Director.

- Working closely with the Scientific Advisory Committee, completed the full process of request for letters of interest, full proposals, chaired the first meeting of the Portfolio Committee, and developed recommendation for the Board.
- Negotiated with Chiron / Pathogenesis GATB's buyout of PA824
- Organized the first GATB seminar on Quinolones, in Washington DC, in close collaboration with the SAC
- Established collaborative relationship with Bayer AG, Pharmacia and Bristol-Myers Squibb
- Established collaborative relationship with the European Union, Research –Directorate, which culminated in the mention of the GATB in the Ministerial Council Resolution
- Established two European Networks of the GATB in France and Belgium that can be leveraged for financing from the European Union
- Nursed and maintained relationship with the R&D coalition of the High Burden Countries. Represents the GATB in the Technical Committee
- Represented the Global Alliance in the Global Drug Facility and seats in the Technical Review Committee
- Worked in collaboration with ALA and Advocacy Director, secured monitoring in Stop TB Now Act introduced to US Congress, and which should enable GATB to receive funding through USAID
- Represented the GATB at the various meetings and to different organization
- Chaired the new Drugs Working Group, and seats on the Coordinating Board of the Stop TB Initiative

As CEO of FIND

Established the organization as among the Founding Members, became its first CEO in 2003 and run it up to 2012. Grew the Organization from 3 FTE in 2003 up to 65 in 2011.

Moved FIND to be recognized by the Swiss Government as Other International Organization in 2011 in light of 23 MOU with HEC Ministries of Health : broad scope TB HIV Malaria , having opened FIND offices in Kampala and New Delhi.

Got 5 new TB technologies endorsed by WHO and rolled them out in 23 Countries.

FIND signed more than 70 Cooperative Agreements with private Companies ; 15 International Organizations : established 18 clinical trials site over 3 Continents

Launched and maintained a long term program on Quality Assurance of Malaria Rapid tests in collaboration with CDC and WHO .This annual report is utilized by MOH of Malaria Endemic Countries as essential guide for annual purchase of Malaria RDT.

In Sleeping Sickness in collaboration with WHO and AU launched a very ambitious Program on Sleeping Sickness advocacy in Africa and got first Molecular Technology endorsed by WHO for diagnosing Human and Animal Trypanosomiasis.

He participated at more than 80 International Meeting as speaker presenter or chair of various Meetings.

He published extensively in peer Reviewed journals on TB Malaria Sleeping Sickness and laboratory strengthening issues.

As COO of ASLM

Was a co founding member of this Organization and Member of its Board from 2010 to 2011.

As COO helped in the drafting of the ASLM SOP : was instrumental in building its initial continental and international Partnerships : EDCT WHO Global Laboratory Initiative.

Attended various international meetings and organized the POC Meeting in Addis Abeba.

AS Chair of NEXT2PEOPLE

Was a Founder of the Swiss based Non for profit Foundation NEXT2PEOPLE. (www.next2people.org).

Currently NEXT is a Subcontractor to URC for various projects : Lesotho (Prevalence Survey) South Africa (TBSAP) and Malawi (Laboratory Strenghtening). In 2018 was among the Founding members of Next2People South Africa and 2019 Next2People Ethiopia .

Next2People focus is mainly in Laboratory Strenghtening PPM ands Case Finding.

Next2People is currently partnering with other NGO and preparing for submission to Global Fund Catalytic Funding for TB in Innovative Laboratory Strenghtening and Public Private Mix projects,

Languages

Italian – Mother tongue

French – Fluent, Proficiency in spoken and written language

English – Fluent, Proficiency in spoken and written language

Spanish – Basic understanding of the spoken language

Amharic / Tigrina – fluent proficiency in spoken and written language

Arabic – basic understanding of the spoken language

List of Publications

1. G. Roscigno, Y. Hersi, V. Pagani, M. Leali, L. Pelati – “A computer simulation model of tuberculosis epidemiology applied to Somalia”; Abstract 3/178, 1st Congress of Mediterranean Society of Therapy, Florence – Italy, June 1984
2. G. Roscigno – “Triple drug combination in the treatment of pulmonary tuberculosis, preliminary results of toxicity”; 31st Annual Meeting & Scientific Conference Association of Physicians of East and Central Africa, Mombasa, June 1984
3. H. Delome, P. Blin, G. Roscigno, M. Merlin, L. Senthiles – « Intérêt des enquêtes tuberculiques par sondage. A propos d’une enquête réalisée dans les écoles de Yaoundé » ; Le bulletin de liaison OCEAC, hors-série, 1985, Quatrième partie 15^{ème} conférence technique (p : 28-33)
4. G. Roscigno – « L’unité de l’association de trois médicaments majeurs : Rifampicin, Isoniazide, Pyrazinamide dans le traitement de la tuberculose pulmonaire » ; Le bulletin de liaison OCEAC, hors série, 1985, Quatrième partie 15^{ème} conférence technique (p : 40-42)
5. M. Nuti, G. Roscigno – “New approaches in immunology, diagnosis and treatment of leprosy”; Poster Session – Journées Médicales de Dakar, 1985.
6. M. Nuti, G. Roscigno – “The phenolic glycolipid test in leprosy patients from different areas”; Poster Session International Congress of Infectious Diseases, Egypt, 1985
7. C. Di Bari, G. Pastre, G. Roscigno, P. Schechter, A. Sjoersdama – « Late stage African trypanosomiasis and Eflornitine”; Annals of Internal Medicine, Volume 105, Nr.5 (P803-804) November 1986
8. W. Naamara, L. J. Da Costa, L. O. Ndinja-Achola, A.R. Ronald, F.A. Plumer, H; Nzanze, G; Roscigno – “Treatment of gonococcal urethritis with Rifampicin (Rif), Erythromycin (Ery) combination in Nairobi”; Poster Session – 2nd World Congress on Sexually Transmitted Diseases, Paris, 1986
9. G. Roscigno – “L’intérêt des associations fixes dans le traitement de la tuberculose pulmonaire”; Séminaire sub-régional sur le traitement de la tuberculose pulmonaire, Abidjan, February 1987
10. G. Roscigno – « L’epidemiologia tubercolare nel mondo » ; Simposio : La tubercolosi, attuale epidemiologia e i nuovi concetti di immunologia clinica. Università degli Studi di Roma, La Sapienza, Aprile 3, 1987
11. M. Nuti, G. Luzi, A. De Felici, G. Roscigno, J. P. Puraud, M. Merlin – « Prevalence of antibodies to HTLV-II and HTLV-III in some African areas »; Poster Session – TH22 Second International Symposium AIDS and Associated Cancers in Africa, October 1987, Naples

12. M. Nuti, A. De Felici, M. Von Axell-Castelli, G. Roscigno – « False HIV positivity in leprosy »; 13th International Leprosy Congress, Amsterdam 1988
13. M.J. Omwega, D. E. Oyoo, M.O. Oloo, R.T. Thiong'o, G. Roscigno – “Fixed dose drug combination regimen in the treatment of pulmonary tuberculosis on a wholly ambulatory basis”; Abstract 05/88, 9th Annual Medical Scientific Conference, Nairobi, February 1988
14. G. Roscigno – Eflornitine (DFMO) in the treatment of human trypanosomiasis due to *T. gambiense*”; Yaounde, OCEAC Epidemiological Meeting, October 1988
15. J. Perriens, M. St Louis, Y. Mukadi, C. Brown, J. Prignot, F. Pouthier, F. Portaels, J. C. Williame, J. Mandala, M. Kaboto, R. Ryder, G. Roscigno, P. Piot – “Pulmonary tuberculosis in the HIV infected patients in Zaire”; *N. Engl. J. Med* 1995, Volume 332, Nr. 12 (p:779-781)
16. B. Ji, C. Truffot-Pernot, M.C. Lacroix, M. Raviglione, R. O'Brien, P. Olliaro, G. Roscigno, J. Grosset – “Effectiveness of Rifampin, Rifabutin and Rifapentine for preventive therapy of tuberculosis in mice”; *Am. Rev. Respir. Dis*, 1993 (p. 1541-1546)
17. « Economics of TB Drg Development » ; The Global Alliance for TB Drug Development , chair: Dr G. Roscigno, publication on line : www.tballiance.org, 2001
18. Scientific Blueprint for TB Drug Development; Tuberculosis – Volume 81, Supplement 1, 2001.

Giorgio Roscigno :Selected recent publications

Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities (*Clin. Microbiol. Rev.* April 2011 vol. 24 no. 2 314-3501 April 2011)

1. Linda M. Parsons¹,
2. Ákos Somoskövi²,
3. Cristina Gutierrez²,
4. Evan Lee²,
5. C. N. Paramasivan²,
6. Alash'le Abimiku³,
7. Steven Spector⁴,
8. Giorgio Roscigno² and
9. John Nkengasong^{1,*}

Laboratory systems and services are critical in global health: time to end the neglect?

Am. J. Clin. Pathol.

Am J Clin Pathol 2010 Sep;134(3):368-73

John N Nkengasong, Peter Nsubuga, Okey Nwanyanwu, Guy-Michel Gershy-Damet, Giorgio Roscigno, Marc Bulterys, Barry Schoub, Kevin M DeCock, Deborah Bix

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.

Antimicrob. Agents Chemother.

Antimicrob Agents Chemother 2010 Aug 1;54(8):3390-4. Epub 2010 Jun 1.

Simbarashe P Zvada, Jan-Stefan Van Der Walt, Peter J Smith, P Bernard Fourie, Giorgio Roscigno, Denis Mitchison, Ulrika S H Simonsson, Helen M McIlleron

"Piggy-backing" on diagnostic platforms brings hope to neglected diseases: the case of sleeping sickness.

PLoS Negl Trop Dis

PLoS Negl Trop Dis 2010 25;4(5):e715. Epub 2010 May 25.

Joseph Mathu Ndung'u, Sylvain Bieler, Giorgio Roscigno

Progress towards improved tuberculosis diagnostics for developing countries.

Lancet

Lancet 2006 Mar;367(9514):942-3

Mark D Perkins, Giorgio Roscigno, Alimuddin Zumla

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.

Am. J. Respir. Crit. Care Med.

Am J Respir Crit Care Med 2005 Jul 1;172(1):128-35. Epub 2005 Apr 1.

Frik A Sirgel, P Bernard Fourie, Peter R Donald, Nesri Padayatchi, Roxana Rustomjee, Jonathan Levin, Giorgio Roscigno, Jennifer Norman, Helen McIlleron, Denis A Mitchison

Joining forces to develop weapons against TB: together we must.

Bull. World Health Organ.

Bull World Health Organ 2002 ;80(6):429

Maria Freire, Giorgio Roscigno

Giorgio Roscigno--senior advisor to the Global Alliance for TB Drug Development. Interviewed by Pam Das.

Lancet Infect Dis

Lancet Infect Dis 2002 Jun;2(6):377-80

Giorgio Roscigno